Caption Management’s Esperion Therapeutics ESPR Stock Holding History

Caption Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-31,600	Closed	-$76.8K	–	1335
2023 Q4	$94.5K	Buy	+31,600	New	+$41K	﹤0.01%	1181
2022 Q3	–	Sell	-12,300	Closed	-$84.5K	–	1598
2022 Q2	$78K	Buy	+12,300	New	+$69.7K	﹤0.01%	1314
2021 Q3	–	Sell	-25,589	Closed	-$373K	–	1591
2021 Q2	$542K	Buy	25,589 +939	+4%	+$22.6K	0.01%	1024
2021 Q1	$691K	Buy	+24,650	New	+$727K	0.01%	752
2020 Q4	–	Sell	-3,000	Closed	-$111K	–	1060
2020 Q3	$111K	Sell	3,000 -18,504	-86%	-$733K	﹤0.01%	944
2020 Q2	$1.1M	Buy	21,504 +7,804	+57%	+$327K	0.04%	512
2020 Q1	$431K	Buy	+13,700	New	+$723K	0.02%	572
2019 Q4	–	Sell	-4,400	Closed	-$198K	–	881
2019 Q3	$161K	Buy	+4,400	New	+$174K	0.01%	605
2019 Q1	–	Sell	-15,000	Closed	-$690K	–	615
2018 Q4	$690K	Buy	+15,000	New	+$723K	0.06%	302

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Caption Management's ESPR Position: Q1 2024 in Review

Caption Management sold out of Esperion Therapeutics (ESPR) in Q1 2024, closing a stake of 31,600 shares — an estimated $76.8K sold.

Caption Management first reported a position in ESPR in Q4 2018 and held it in 9 quarters. The position peaked at $1.1M in Q2 2020. 153 funds tracked by Wall St. Rank hold ESPR as of Q1 2024.

Caption Management reported no remaining Esperion Therapeutics position as of Q1 2024 after selling out during the quarter.
Caption Management sold 31,600 Esperion Therapeutics shares in Q1 2024, an estimated $76.8K.
Caption Management first reported a position in Esperion Therapeutics in Q4 2018 and held it in 9 quarters.
Caption Management's Esperion Therapeutics position peaked at $1.1M in Q2 2020.
153 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.